X-Message-Number: 32074
From: "John de Rivaz" <>
Subject: Transtime's spin-off's subsidiary
Date: Fri, 16 Oct 2009 17:19:28 +0100


BioTime, Inc. (OTCBB:BTIM) announced today that it has organized a new 
subsidiary, OncoCyte Corporation, for the purpose of developing novel 
therapeutics for the treatment of cancer based on stem cell technology. BioTime 
will license certain technology to the new company restricted to the field of 
cell-based cancer therapies, including early patent filings on targeting stem 
cells to malignant tumors. A private investor has purchased 3,000,000 common 
shares of OncoCyte for $2 million, representing an initial 15% stake in the new 
company, and the investor has the option of purchasing an additional 3,000,000 
common shares for $2 million on or before April 15, 2010, based on an agreed 
initial market cap of approximately $15,000,000. 

more on http://www.investorcalendar.com/includes/PRNPressRelease.asp?ID=1539801

-- 
Sincerely, John de Rivaz:  http://John.deRivaz.com for websites including
Cryonics Europe, Longevity Report, The Venturists, Porthtowan, Alec Harley
Reeves - inventor, Arthur Bowker - potter, de Rivaz genealogy,  Nomad .. and
more

 Content-Type: text/html;

[ AUTOMATICALLY SKIPPING HTML ENCODING! ] 

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=32074